The main raw materials of contrast media in the upstream market are bulk drugs such as iohexol and barium sulfate. Iohexol segment market is small, suppliers and purchasers are relatively concentrated in this market and purchasing prices are settled by manufacturers. The main iohexol suppliers are the three, so raw material purchase of manufacturing enterprises is relatively concentrated. If bulk drug suppliers increase prices, manufacturing enterprises have difficulties to change other suppliers, so they may face risks relating to rising production cost. Therefore upstream suppliers have strong bargaining power in contrast media industry.
The downstream markets of contrast media industry mainly are drug dealers or hospitals. The purchasing prices are settled by the two parties because of quantity buying or long-term buying, or customers can purchase by invitation to bid, at this time customers have relatively stronger bargaining power.
With the society development, and the improvement of people’s living standards and constant popularization of common sense about medical treatment as well as the promotion of new medial healthcare reform package, the number of imaging equipments is increasing in China, the usage volume of contrast media is on the rapid growing trend and more and more participants enter this market. Potential entrants pose greater threats to enterprises in this industry.
Currently domestic enterprises with large market scale in contrast media field are few, foreign capital enterprises occupy more than half of Chinese market and are in a leading position; while domestic enterprises represented by Yangtze River Pharmaceutical, Jiangsu Hengrui Medicine and BEILU Pharmaceutical realized the rapid expansion and increased market shares by virtue of cost performance advantage and local academic marketing.
According to the procurement of contrast media from sample hospitals in 16 cities, the CT contrast media with market shares ranking top 4 in China are iohexol, iopromide, ioversol and iodixanol successively, with market shares of 20.23%, 20.21%, 19.32% and 9.32% respectively.
According to the sales of enterprises, there are no big differences between Chinese contrast media market and international market. Iohexol produced by Shanghai Amersham Health (a subsidiary of GE Healthcare) and iodine by Schering Pharmaceutical Ltd.(Guangdong) occupy the most market shares, and iohexol by Yangtze River Pharmaceutical, iopamidol by Shanghai Bracco Sine Pharmaceutical Corp. Ltd and ioversol by Jiangsu Hengrui Medicine are placed on the second group, and iohexol produced by GUERBET LABS (a French company) and BEILU Pharmaceutical and meglumine diatrizoate by Shanghai Xudong Haipu Pharmaceutical Co., Ltd. rank third group. Their market shares of main products and proportion of their products in sampled hospitals are listed in the following:
Drug Name Ranking Market Shares (%) Product proportion in Enterprises iohexol 1 20.23 Shanghai Amersham Health (GE) 46.84%; Yangtze River Pharmaceutical 32.45%; BEILU Pharmaceutical 14.53%; iopromide 2 20.21 Schering Pharmaceutical (Guangzhou)100% ioversol 3 19.32 America Mallinckrodt Inc. and Canada Tyco Healthcare (33%)；Jiang Su Heng Rui Medicine Co., Ltd (66.26%) iopamidol 4 11.08 Shanghai Bracco Sine Pharmaceutical ( 31%); Bracco SPA (69%); Gadopentetate dimeglumine 5 10.19 Schering Pharmaceutical (Guangzhou) 38.55 %, Beijing BEILU Pharmaceutical 34.87%, Consun Pharmaceutical Group 20.25% and Shanghai Xudong Haipu Pharmaceutical 5.92 %; iodixanol 6 9.32 Shanghai Xudong Haipu Pharmaceutical 63%; Schering Pharmaceutical Ltd.(Guangdong) 21%; Shanghai Bracco Sine Pharmaceutical 9%; Source: Huidian Research; Sampled Hospitals’ Drug Use Database of Chinese Pharmaceutical Association Drug Name Ranking Market Shares (%) Product proportion in Enterprises
Gadopentetate dimeglumine 1 82.84 Schering Pharmaceutical Ltd.(Guangdong) 38.55 %; BEILU Pharmaceutical 34.87; Consun Pharmaceutical Group Limited 20.25%; Shanghai Xudong Haipu Pharmaceutical 5.92 %; Gadodiamide 2 15.34 GE Healthcare100% gadobenate dimeglumine 3 0.94 Shanghai Bracco Sine Pharmaceutical 11%; BRACCO(IT) 89% Gadopentetate meglumine 4 0.88 GUERBET LABS.(FR)100% Source: Huidian Research; Sampled Hospitals’ Drug Use Database of Chinese Pharmaceutical Association
As for domestic MRI contrast media market, gadopentetate dimegulmine still plays a leading role. Schering Pharmaceutical (Guangdong) accounts for less than 40% of market shares, BEILU Pharmaceutical follows behind it after imitating the same products of Schering. GE Healthcare falls behind Schering Pharmaceutical in domestic MRI market, with only about 10% of market shares, and GE is surpassed by BEILU Pharmaceutical, Consun Pharmaceutical Group Limited follows behind GE Healthcare.
- Yangtze River Pharmaceutical Group
- BEILU Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.
- China Resources Double-crane Pharmaceutical Co., Ltd.
- Shanghai Xudong Haipu Pharmaceutical Co., Ltd.
Table of Contents for Report "Research and Development Forecast of China Contrast Media (Contrast Agent) Market, 2015-2020"
Table of Contents
1. Development Overview of Contrast Media Industry
1.1 Overview of Industry
1.1.1 Product Concept
1.1.2 Product Classification
1.2 Industry China
2. Development Overview of Global Contrast Media Industry
2.1 Development Status
2.2 Patent Application of Contrast Media in global
3. Environment Analysis of China’s Contrast Media Industry
3.1 China’s Economic Development Environment
3.1.1 Situation of agricultural production is sound
3.1.2 Industrial Production Increased steadily
3.1.3 Growth Rate of Fixed Asset Investment Slowed Down in High Position
3.1.4 Commodity consumption increased steadily
3.1.5 Foreign trade surplus continues to increase
3.1.6 Consumption Price is Stable Basically
3.1.7 Resident Income Grows Steadily
3.1.8 Continually optimize structure
3.1.9 Monetary credit increased steadily
3.2 Policy Environment
3.2.1 National Basic Medical Insurance, Employment Injury Insurance and Maternity Insurance Drug Catalogue
3.2.2 Suggestions on Consolidating Essential Medicine System and New Operation Mechanism of Grass Roots
3.2.3 Revision of Pharmaceutical Administration Law
3.3 Domestic Technological Level of Contrast Media
3.3.1 Technical Status
3.3.2 Patent Application in China
3.3.3 Technology Trends
4. Analysis on China’s Contrast Media Industry
4.1 Domestic Market Status and Forecast
4.2 Segment Products
4.2.1 Much Attention on Iodized Salt Type of Products
4.2.2 Ultravist Dominates Iopromide Market
4.2.3 Imported and Domestic Iohexol Have Equal Shares
4.2.4 Iopamidol vs. Ioversol
4.2.5 Differences between Domestic and Overseas Gadopentetate Dimeglumine
4.2.6 Situation of tripartite confrontation of iohexol
4.2.7 Imitation of iopromide should catch up in China
4.2.8 Home-made ioversol outshines
4.2.9 Iodixanol grows rapidily
4.3 Factors Affecting Contrast Media Development
4.3.1 Improvement of Social Economy
4.3.2 Wide Application of Imaging Diagnostic and Treatment Equipment
4.3.3 Improvement of Imaging Diagnostic and Treatment Method
4.3.4 Changes of Seeing a Doctor
5. Competitive Landscape of China’s Contrast Media Industry
5.1 Competitiveness Analysis
5.1.1 Upstream Bargaining Power
5.1.2 Periodic Fluctuation of Consumers’ Bargaining Power
5.1.3 Potential Entrant
5.1.4 Competition in the Industry
5.2 Concentration Ratio of Contrast media Industry
5.2.1 Concentration Ratio of China’s CT Contrast media Market
5.2.2 Market Concentration Ratio of MRI (Magnetic Resonance Imaging) Contrast Media in China
6. Import and Export Data of Contrast Media Products
6.1 Import and Export Data of X-Ray Contrast Media and Diagnostic Reagent, 2011-2015
6.2 Import Sources and Export Destinations of X-Ray Contrast Media and Diagnostic Reagent, 2014
6.2.1 Import Sources of X-ray Contrast Media and Diagnostic Reagent, 2014
6.2.2 Export Destinations of X-ray Contrast Media and Diagnostic Reagent, 2014
7. Domestic Major Contrast Media Manufacturing Enterprises
7.1 Yangtze River Pharmaceutical Group
7.1.1 Company Profile
7.1.2 Main Business
7.1.3 Competitive Edge
7.1.4 Business Performance
7.1.5 Future Development Strategy
7.2 BEILU Pharmaceutical Co., Ltd.
7.2.1 Company Profile
7.2.2 Main Business
7.2.3 Competitive Edge
7.2.4 Business Performance
7.2.5 Future Development Strategy
7.3 Jiangsu Hengrui Medicine Co., Ltd.
7.3.1 Company Profile
7.3.2 Main Business
7.3.3 Competitive Edge
7.3.4 Business Performance
7.3.5 Future Development Strategy
7.4 China Resources Double-crane Pharmaceutical Co., Ltd.
7.4.1 Company Profile
7.4.2 Main Business
7.4.3 Competitive Edge
7.4.4 Business Performance
7.4.5 Market Structure of Cardiac Ultrasound Contrast Media
7.5 Shanghai Xudong Haipu Pharmaceutical Co., Ltd.
7.5.1 Company Profile
7.5.2 Main Business
7.5.3 Product Performance
8. Investment and Development Trend of Contrast Media Industry
8.1 Investment Opportunities
8.1.1 Rising Health Consciousness
8.1.2 Increasing Number of Medical Treatment Equipment (MRI Equipment)
8.1.3 The Increase of Enhancement Scan Usage Amount
8.2 Investment Risks
8.3 Development Trend of China’s Contrast Media Industry
8.3.1 X-Ray CT Contrast Media
8.3.2 MRI Contrast Media
8.3.3 Ultrasound Contrast Media
8.4.1 Large-Scale and Specialized Enterprise Development
8.4.2 Strengthen Technology R&D
8.4.3 Scientific Enterprise Management
8.4.4 Build Brand Awareness